These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 11734711)

  • 21. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
    Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
    Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
    Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison on the levels of human serum antibody against Neisseria meningitidis serogroup C measured using serum bactericidal assay and ELISA].
    Zhu BQ; Xu L; Zhou HJ; Shao ZJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 May; 33(5):521-4. PubMed ID: 22883183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
    Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
    Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants.
    Rennels M; King J; Ryall R; Papa T; Froeschle J
    Pediatr Infect Dis J; 2004 May; 23(5):429-35. PubMed ID: 15131466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
    Gorringe AR; Taylor S; Brookes C; Matheson M; Finney M; Kerr M; Hudson M; Findlow J; Borrow R; Andrews N; Kafatos G; Evans CM; Read RC
    Clin Vaccine Immunol; 2009 Aug; 16(8):1113-20. PubMed ID: 19553555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
    Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
    Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.
    Rennels MB; Edwards KM; Keyserling HL; Reisinger K; Blatter MM; Quataert SA; Madore DV; Chang I; Malinoski FJ; Hackell JG; Paradiso PR
    Pediatr Infect Dis J; 2001 Feb; 20(2):153-9. PubMed ID: 11224833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cuban Meningococcal Vaccine VA-MENGOC-BC:30 Years of Use and Future Potential.
    Sierra-González VG
    MEDICC Rev; 2019 Oct; 21(4):19-27. PubMed ID: 32335565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency.
    van den Broek B; van Els CACM; Kuipers B; van Aerde K; Henriet SS; de Groot R; de Jonge MI; Langereis JD; van der Flier M
    Clin Exp Immunol; 2019 Dec; 198(3):381-389. PubMed ID: 31487400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
    Snape MD; Philip J; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Kittel C; Toneatto D; Dull PM; Pollard AJ
    Pediatr Infect Dis J; 2013 Oct; 32(10):1116-21. PubMed ID: 23958808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine.
    Naess LM; Aarvak T; Aase A; Oftung F; Høiby EA; Sandin R; Michaelsen TE
    Vaccine; 1999 Feb; 17(7-8):754-64. PubMed ID: 10067680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines.
    Sikkema DJ; Friedman KE; Corsaro B; Kimura A; Hildreth SW; Madore DV; Quataert SA
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):764-8. PubMed ID: 10973451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
    Flacco ME; Manzoli L; Rosso A; Marzuillo C; Bergamini M; Stefanati A; Cultrera R; Villari P; Ricciardi W; Ioannidis JPA; Contopoulos-Ioannidis DG
    Lancet Infect Dis; 2018 Apr; 18(4):461-472. PubMed ID: 29371070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.
    Boutriau D; Poolman J; Borrow R; Findlow J; Domingo JD; Puig-Barbera J; Baldó JM; Planelles V; Jubert A; Colomer J; Gil A; Levie K; Kervyn AD; Weynants V; Dominguez F; Barberá R; Sotolongo F
    Clin Vaccine Immunol; 2007 Jan; 14(1):65-73. PubMed ID: 17065257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.